Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo

British Journal of Cancer

Volumn 95, Issue 9, 2006, Pages 1212-1219

  Theys, J ^a   Pennington, O ^b   Dubois, L ^a   Anlezark, G ^f   Vaughan, T ^f   Mengesha, A ^a   Landuyt, W ^c   Anne J ^d   Burke, P J ^e   Durre P ^g   Wouters, B G ^a   Minton, N P ^b   Lambin, P ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c Gasthuisberg CDG   (Belgium)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e Enact Pharma   (United Kingdom)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

^g UNIVERSITY OF ULM   (Germany)

Author keywords

Clostridium; Conjugation; Hypoxia; Nitroreductase; Tumour

Indexed keywords

NITROREDUCTASE; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLOSTRIDIUM; CLOSTRIDIUM SPOROGENES; CONTROLLED STUDY; ENZYME ISOLATION; FEMALE; GENE TARGETING; GENETIC ENGINEERING; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; CELL LINE; CELL SURVIVAL; CLOSTRIDIUM; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE THERAPY; GENETIC VECTORS; HCT116 CELLS; HUMANS; MICE; MICE, INBRED STRAINS; MICE, NUDE; NITROREDUCTASES; PRODRUGS; RECOMBINANT PROTEINS; SPORES, BACTERIAL; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33750480202     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603367     Document Type: Article

References (32)

1. Anlezark GM, Vaughan T, Fashola-Stone E, Michael NP, Murdoch H, Sims MA, Stubbs S, Wigley S, Minton NP (2002) Bacillus amyloliquefaciens orthologue of Bacillus subtilis ywrO encodes a nitroreductase enzyme which activates the prodrug CB 1954. Microbiology 148: 297-306
2. Barbe S, Van Mellaert L, Theys J, Geukens N, Lammertyn E, Lambin P, Anne J (2005) Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment. FEMS Microbiol Lett 246: 67-73
3. Bettegowda C, Dang LH, Abrams R, Huso DL, Dillehay L, Cheong I, Agrawal N, Borzillary S, McCaffery JM, Watson EL, Lin KS, Bunz F, Baidoo K, Pomper MG, Kinzler KW, Vogelstein B, Zhou S (2003) Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci USA 100: 15083-15088
4. Carey RW, Holland JF, Whang HY, Neter E, Bryant B (1967) Clostridial oncolysis in man. Eur J Cancer 3: 37-46
5. Carter GP, Purdy D, Williams P, Minton NP (2005) Quorum sensing in Clostridium difficile: analysis of a luxS-type signalling system. J Med Microbiol 54: 119-127
6. Chambers SP, Prior SE, Barstow DA, Minton NP (1988) The pMTL niccloning vectors. I. Improved pUC polylinker regions to facilitate the use of sonicated DNA for nucleotide sequencing. Gene 68: 139-149
7. Cui W, Gusterson B, Clark AJ (1999) Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway. Gene Therapy 6: 764-770
8. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B (2001) Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 98: 15155-15160
9. Djeha AH, Hulme A, Dexter MT, Mountain A, Young LS, Searle PF, Kerr DJ, Wrighton CJ (2000) Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther 7: 721-731
10. Djeha AH, Thomson TA, Leung H, Searle PF, Young LS, Kerr DJ, Harris PA, Mountain A, Wrighton CJ (2001) Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors. Mol Ther 3: 233-240
11. Fox ME, Lemmon MJ, Mauchline ML, Davis TO, Giaccia AJ, Minton NP, Brown JM (1996) Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Therapy 3: 173-178
12. Gericke D, Dietzel F, Konig W, Ruster I, Schumacher L (1979) Further progress with oncolysis due to apathogenic clostridia. Zentralbl Bakteriol [Orig A] 243: 102-112
13. Knox RJ, Boland MP, Friedlos F, Coles B, Southan C, Roberts JJ (1988) The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4- dinitrobenzamide (CB1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinine) (EC 1.6.99.2). Biochem Pharmacol 37(24): 4671-4677
14. Koumenis C, Naczki C, Koritzinsky M, Rastani S, Diehl A, Sonenberg N, Koromilas A, Wouters BG (2002) Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol Cell Biol 22: 7405-7416
15. Lambin P, Theys J, Landuyt W, Rijken P, van der Kogel A, van der Schueren E, Hodgkiss R, Fowler J, Nuyts S, de Bruijn E, Van Mellaert L, Anne J (1998) Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours. Anaerobe 4: 183-188
16. Lemmon MJ, van Zijl P, Fox ME, Mauchline ML, Giaccia AJ, Minton NP, Brown JM (1997) Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Therapy 4: 791-796
17. Liu SC, Minton NP, Giaccia AJ, Brown JM (2002) Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Therapy 9: 291-296
18. Mermelstein LD, Welker NE, Bennett GN, Papoutsakis ET (1992) Expression of cloned homologous fermentative genes in Clostridium acetobutylicum ATCC 824. Biotechnology (New York) 10: 190-195
19. Michael NP, Brehm JK, Anlezark GM, Minton NP (1994) Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its over-expression in Escherichia coli K12. FEMS Microbiol Lett 124: 195-202
20. Minton NP (2003) Clostridia in cancer therapy. Nat Rev Microbiol 1: 237-242
21. Minton NP, Mauchline ML, Lemmon MJ, Brehm JK, Fox M, Michael NP, Giaccia A, Brown JM (1995) Chemotherapeutic tumour targeting using clostridial spores. FEMS Microbiol Rev 17: 357-364
22. Mose JR, Mose G (1964) Oncolysis by clostridial activity of Clostridium butyricum (M-55) and other non-pathogenic clostridia against the Ehrlich carcinoma. Cancer Res 24: 212-216
23. Oultram JD, Peck H, Brehm JK, Thompson DE, Swinfield TJ, Minton NP (1988) Introduction of genes for leucine biosynthesis from Clostridium pasteurianum into C. acetobutylicum by cointegrate conjugal transfer. Mol Gen Genet 214: 177-179
24. Palmer DH, Milner AE, Kerr DJ, Young LS (2003) Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil. Br J Cancer 89: 944-950
25. Pipiya T, Sauthoff H, Huang YQ, Chang B, Cheng J, Heitner S, Chen S, Rom WN, Hay JG (2005) Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Therapy 12: 911-917
26. Purdy D, O'Keeffe TA, Elmore M, Herbert M, McLeod A, Bokori-Brown M, Ostrowski A, Minton NP (2002) Conjugative transfer of clostridial shuttle vectors from Escherichia coli to Clostridium difficile through circumvention of the restriction barrier. Mol Microbiol 46: 439-452
27. Shen BH, Hermiston TW (2005) Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Therapy 12: 902-910
28. Theys J, Landuyt W, Nuyts S, Van Mellaert L, Bosmans E, Rijnders A, Van Den Bogaert W, van Oosterom A, Anne J, Lambin P (2001b) Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunol Med Microbiol 30: 37-41
29. Theys J, Landuyt W, Nuyts S, Van Mellaert L, van Oosterom A, Lambin P, Anne J (2001a) Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther 8: 294-297
30. Williams DR, Young DI, Young M (1990) Conjugative plasmid transfer from Escherichia coli to Clostridium acetobutylicum. J Gen Microbiol 136: 819-826
31. Wilson WR, Pullen SM, Hogg A, Helsby NA, Hicks KO, Denny WA (2002) Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res 62: 1425-1432
32. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer research (UKCCR) guidelines for welfare of animals in experimental neoplasia [second edition]. Br J Cancer 77: 1-10